USD10
NGEN Shares
About NervGen Pharma Corp.NervGen Pharma Corp is a clinical-stage biopharmaceutical company developing first-in-class neuroreparative therapeutics for spinal cord injury and other traumatic and neurologic conditions. The Company's principal business activity is the discovery, development and commercialization of neuroreparative therapeutics for spinal cord injury (SCI) and other neurotraumatic and neurologic conditions. NervGen's initial target indication is SCI. The company's pipeline products include NVG-291 and NVG-300.
USD10
NGEN Shares
About NervGen Pharma Corp.NervGen Pharma Corp is a clinical-stage biopharmaceutical company developing first-in-class neuroreparative therapeutics for spinal cord injury and other traumatic and neurologic conditions. The Company's principal business activity is the discovery, development and commercialization of neuroreparative therapeutics for spinal cord injury (SCI) and other neurotraumatic and neurologic conditions. NervGen's initial target indication is SCI. The company's pipeline products include NVG-291 and NVG-300.
Stats
TRADING WINDOW
Closed
OPENS AT
Oct 14 at 1:30 PM UTC
MARKET CAP
$173.11M
OPEN PRICE
Not enough data
LOW (1Y)
$1.58
HIGH (1Y)
$6.30
LOW (24H)
$1.61
HIGH (24H)
$1.79
VOLUME (24H)
$372.34K
123.88%
Price history
Time | Price | Change |
|---|---|---|
Today | Not enough data | Not enough data |
1 Day | $1.79 | |
1 Week | $1.75 | |
1 Month | $2.16 | |
1 Year | $5.97 |
Past performance is not a reliable indicator of future results.
Discover more
Popular prediction markets
Popular price predictions
Legal
Information is provided for informational purposes only, and is not investment advice. This is not an invitation, inducement or recommendation to buy any particular asset, or to employ any particular investment strategy. Coinbase makes no representation as to the accuracy, suitability or validity of any information provided.All ticker names are trademarks of their respective holders. Any ticker reference does not imply affiliate with or endorsement by a third-party. Real-time prices are sourced from third parties, but not from all markets. Source: Nasdaq Last Sale. Morningstar data ©2026.